Understanding how stress affects immune response in aggressive breast cancer
Official title: Identifying the role of interferon and interferon-regulated chemokines in stress-induced immunosuppression in triple negative breast cancer
Funded at Roswell Park Cancer Institute Corp · NIH-10727051 · Data updated 2026-11-12
This study is looking at how stress affects the immune system in people with triple negative breast cancer, to see if managing stress can help make cancer treatments work better.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $173,500 |
| NIH project number | 1R03TR004607-01 |
| Project ID | NIH-10727051 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with triple negative breast cancer who may be experiencing significant psychosocial stress.
✕Less likely to help
Patients with other types of breast cancer or those not experiencing stress-related issues may not benefit from this research.
What this research studies
This research investigates the impact of stress on the immune response in patients with triple negative breast cancer (TNBC), a particularly aggressive form of breast cancer. It focuses on how stress-induced changes in certain molecules may hinder the effectiveness of immune checkpoint inhibitors, which are treatments designed to help the immune system fight cancer. By studying the relationship between psychosocial stress and immune response, the research aims to identify new strategies to improve treatment outcomes for TNBC patients. The approach includes examining the expression of specific chemokines that are crucial for attracting immune cells to tumors.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for triple negative breast cancer patients, enhancing their response to existing therapies.
How similar studies have gone: Previous research has indicated that stress can negatively impact cancer treatment outcomes, suggesting that this approach may yield valuable insights.
Where this research is happening
-
Roswell Park Cancer Institute Corp
Buffalo, United States Active
Researchers
- Principal investigator: Gandhi, Shipra — Roswell Park Cancer Institute Corp
- Study coordinator: Gandhi, Shipra
Related research
Other NIH-funded projects on the same topics.
-
Stress-related hormonal signals and immune response in a specific breast cancer type
A study in triple-negative breast cancer looks at how stress hormones may weaken the body's immune attack and whether blocking those signals could improve cancer treatment.
-
Investigating how stress affects the immune response in aggressive breast cancer.
This study is looking at how stress affects the immune system's ability to fight triple negative breast cancer and hopes to find ways, like using certain medications, to make treatments work better for patients dealing with this type of cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Linking heavy metal exposure to a tougher breast cancer type (TNBC)
Aimed at understanding how heavy metals like cadmium might trigger a dangerous breast cancer type (TNBC) in people, especially those with BRCA1 risk, to identify possible future treatment strategies.
-
Dormancy in Triple-Negative Breast Cancer: How Liver and Skin Metastases Go Quiet or Reactivate
Researchers will study how dormant cancer cells in liver and skin metastases of triple-negative breast cancer become quiescent or wake up, using organ-on-chip models and single-cell analysis to map chromatin states.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.